# JMT101

Source: https://onco.cc/drugs/jmt101/  
OnCo record `jmt101` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

JMT101 is an experimental monoclonal antibody from Shanghai JMT-Bio in phase 3 trials for non-small-cell lung cancer, aimed at EGFR.

## Summary

JMT101 is a monoclonal antibody developed by Shanghai JMT-Bio. Its target is EGFR (the sponsor names EGFR). The sponsor states: JMT101 is a recombinant humanised anti-EGFR monoclonal antibody, given intravenously (6 mg/kg every two weeks) in combination with osimertinib versus osimertinib alone in EGFR-mutant non-small cell lung cancer. ClinicalTrials.gov describes the intervention as: JMT101 is a recombinant humanized anti-EGFR monoclonal antibody. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06735391 (A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations), in non-small-cell lung cancer. The largest, NCT06735391, plans to enrol 516 participants with primary completion expected 2026-09-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: monoclonal antibody
- Mechanism: JMT101 is a recombinant humanised anti-EGFR monoclonal antibody, given intravenously (6 mg/kg every two weeks) in combination with osimertinib versus osimertinib alone in EGFR-mutant non-small cell lung cancer.

## Sources

- ClinicalTrials.gov: trials of JMT101: https://clinicaltrials.gov/search?intr=JMT101

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)
- trials: [A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations](https://onco.cc/trials/nct06735391/), [Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06319313/), [The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer](https://onco.cc/trials/nct07134205/)

---
JSON: https://onco.cc/api/v1/entities/jmt101.json